A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome (NCT07145060) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome
China105 participantsStarted 2025-09-01
Plain-language summary
This project aims to conduct a prospective, randomized, double-blind, controlled clinical study to clarify the efficacy and safety of the YiQi YangYin Formula in treating patients with primary Sjogren's syndrome (pSS) presenting with Qi and Yin deficiency syndrome, with the expectation of providing a scientific basis for the research and development of new traditional Chinese medicine drugs for the effective treatment of pSS.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged18-75 years old (including the critical value), gender not limited;
* Patients meeting the classification criteria of primary Sjogren's syndrome in ACR/EULAR 2016;
* Patients with dry mouth VAS ≥4 and ESSDAI score \< 5;
* Patients with positive autoantibodies (ANA or anti-SSA antibodies or anti-SSB antibodies or RF) and/or hyperimmunoglobulinemia or increased erythrocyte sedimentation rate;
* Patients meeting the syndrome of qi and Yin deficiency in traditional Chinese medicine;
* The subjects were informed and voluntarily signed the informed consent form.
Exclusion Criteria:
* Patients with a history of hypersensitivity or intolerance to any investigational therapeutic drug;
* Patients diagnosed with secondary Sjogren's syndrome or combined with other connective tissue diseases;
* Patients with severe lesions in the heart, brain, lungs, liver, kidneys, hematopoietic system, etc., as well as those with malignant tumors or infectious diseases;
* Patients who are pregnant, preparing for pregnancy or breastfeeding;
* Patients who have used cholinergic drugs or artificial tears/saliva in last 1 week;
* Patients who have used hydroxychloroquine, total glycosides of Paeonia lactide, Iguratimod, cyclophosphamide, cyclosporine A, tacrolimus, and azathioprine in last 1 month;
* Patients who have used glucocorticoids, methotrexate or mycophenolate mofetil in last 3 months;
* Patients who have used Leflunomide in last 6 months;
* Patients who have u…